Swiss National Bank purchased a new position in Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) during the 2nd quarter, Holdings Channel reports. The institutional investor purchased 172,100 shares of the biopharmaceutical company’s stock, valued at approximately $661,000.
Several other large investors also recently bought and sold shares of CPRX. Gables Capital Management Inc. lifted its position in Catalyst Pharmaceuticals by 1.3% during the second quarter. Gables Capital Management Inc. now owns 486,064 shares of the biopharmaceutical company’s stock valued at $1,869,000 after purchasing an additional 6,300 shares during the period. Lido Advisors LLC grew its stake in Catalyst Pharmaceuticals by 11.8% during the 1st quarter. Lido Advisors LLC now owns 126,403 shares of the biopharmaceutical company’s stock valued at $644,000 after acquiring an additional 13,380 shares in the last quarter. Biltmore Capital Advisors LLC acquired a new position in Catalyst Pharmaceuticals in the 1st quarter valued at about $79,000. BNP Paribas Arbitrage SA acquired a new position in Catalyst Pharmaceuticals in the 1st quarter valued at about $102,000. Finally, Los Angeles Capital Management & Equity Research Inc. lifted its holdings in shares of Catalyst Pharmaceuticals by 122.4% in the 2nd quarter. Los Angeles Capital Management & Equity Research Inc. now owns 94,960 shares of the biopharmaceutical company’s stock worth $365,000 after acquiring an additional 52,260 shares during the last quarter. Institutional investors and hedge funds own 59.81% of the company’s stock.
A number of research analysts recently commented on CPRX shares. SunTrust Banks reaffirmed a “buy” rating and issued a $11.00 target price (up from $9.00) on shares of Catalyst Pharmaceuticals in a research report on Thursday, August 8th. Cantor Fitzgerald raised their target price on shares of Catalyst Pharmaceuticals from $10.00 to $12.00 in a report on Thursday, August 8th. BidaskClub upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 3rd. Finally, Zacks Investment Research upgraded shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a report on Wednesday, July 31st. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $8.54.
Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.07. The company had revenue of $28.84 million for the quarter, compared to analyst estimates of $17.99 million. During the same quarter in the prior year, the company earned ($0.06) earnings per share. The business’s revenue was up 2883900.0% compared to the same quarter last year. Equities research analysts forecast that Catalyst Pharmaceuticals Inc will post 0.34 EPS for the current year.
Catalyst Pharmaceuticals Profile
Catalyst Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome in the United States.
Featured Story: Most Active Stocks
Want to see what other hedge funds are holding CPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Pharmaceuticals Inc (NASDAQ:CPRX).
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.